- Home
- RFM vs COYA Comparison
RFM vs COYA Comparison
Compare RFM & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFM
- COYA
- Stock Information
- Founded
- RFM 2020
- COYA 2020
- Country
- RFM United States
- COYA United States
- Employees
- RFM N/A
- COYA N/A
- Industry
- RFM Finance/Investors Services
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- RFM Finance
- COYA Health Care
- Exchange
- RFM Nasdaq
- COYA Nasdaq
- Market Cap
- RFM 96.4M
- COYA 104.3M
- IPO Year
- RFM N/A
- COYA 2022
- Fundamental
- Price
- RFM $15.67
- COYA $6.08
- Analyst Decision
- RFM
- COYA Strong Buy
- Analyst Count
- RFM 0
- COYA 3
- Target Price
- RFM N/A
- COYA $16.67
- AVG Volume (30 Days)
- RFM 20.7K
- COYA 142.0K
- Earning Date
- RFM 01-01-0001
- COYA 11-06-2024
- Dividend Yield
- RFM 9.74%
- COYA N/A
- EPS Growth
- RFM N/A
- COYA N/A
- EPS
- RFM N/A
- COYA N/A
- Revenue
- RFM N/A
- COYA $9,554,315.00
- Revenue This Year
- RFM N/A
- COYA N/A
- Revenue Next Year
- RFM N/A
- COYA $54.20
- P/E Ratio
- RFM N/A
- COYA N/A
- Revenue Growth
- RFM N/A
- COYA N/A
- 52 Week Low
- RFM $12.89
- COYA $4.75
- 52 Week High
- RFM $16.41
- COYA $10.69
- Technical
- Relative Strength Index (RSI)
- RFM 39.31
- COYA 38.00
- Support Level
- RFM $15.56
- COYA $5.90
- Resistance Level
- RFM $15.99
- COYA $7.50
- Average True Range (ATR)
- RFM 0.12
- COYA 0.50
- MACD
- RFM -0.01
- COYA -0.17
- Stochastic Oscillator
- RFM 25.03
- COYA 10.91
About RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.